Skip to main content


Latest articles

07-05-2020 | Rheumatology | News | Article

Concise self-management hand program effective for SSc patients

Research indicates that a home-based, self-management program that promotes easy hand exercises and gives direction on moisturizing and warming effectively reduces pain and improves function in the hands of patients with systemic sclerosis.

06-05-2020 | Rheumatology | News | Article

IL-6 levels may predict sarilumab efficacy in RA

Sarilumab shows greater efficacy relative to adalimumab or methotrexate monotherapy among rheumatoid arthritis patients with high baseline interleukin-6 levels than it does among those with low or medium levels, study findings indicate.

06-05-2020 | Rheumatology | News | Article

COVID-19 recovery reported in etanercept-treated patient with spondyloarthritis

French researchers report a favorable COVID-19 outcome for an immunocompromised patient with spondyloarthritis treated with the tumor necrosis factor-α inhibitor etanercept.

05-05-2020 | Rheumatology | News | Article

Minimal impact of targeted therapy tapering on AE rates in RA, axSpA

Tapering of biologic DMARDs or Janus kinase inhibitors does not significantly reduce serious infection or serious adverse event rates in people with rheumatoid arthritis or axial spondyloarthritis, meta-analysis data show.

05-05-2020 | Rheumatology | News | Article

​​​​​​​World Scleroderma Foundation issues preliminary advice on SSc and COVID-19

The World Scleroderma Foundation has released preliminary guidance to address questions on COVID-19 in patients with systemic sclerosis.

04-05-2020 | Rheumatology | News | Article

Ixekizumab set for EU approval for radiographic, nonradiographic axSpA

Click through for more information on this announcement

04-05-2020 | Rheumatology | News | Article

COVID-19 outcomes described in patients with large-vessel vasculitis

Researchers outline the impact of COVID-19 in a cohort of Italian patients with large-vessel vasculitis.

04-05-2020 | Rheumatology | News | Article

​​​​​​​Biologic, JAK inhibitor use may not be linked to worse COVID-19 outcomes

The authors of a prospective US case series outline the experience of 86 patients with immune-mediated inflammatory diseases and confirmed or highly suspected COVID-19.

01-05-2020 | Rheumatology | News | Article

CloroCovid-19 results reinforce the need for caution with chloroquine, hydroxychloroquine use

Findings from the phase 2b CloroCovid-19 trial indicate that patients with severe suspected COVID-19 who are treated with high-dose chloroquine have higher rates of death than those given low-dose chloroquine.

01-05-2020 | Rheumatology | News | Article

Disease characteristics predict belimumab response in SLE

High disease activity, short disease duration, and low baseline damage are associated with an increased response to belimumab in patients with systemic lupus erythematosus, real world study data show.

30-04-2020 | Rheumatology | News | Article

Early rheumatologist attention delivers improved RA remission rates

People with rheumatoid arthritis who visit a rheumatologist within the first 6 weeks of experiencing symptoms are more likely to achieve sustained DMARD-free remission than those who wait for 7–12 weeks, suggest observational study results.

30-04-2020 | Rheumatology | News | Article

EULAR provides guidance on managing immunotherapy-related rheumatic irAEs

EULAR has issued recommendations on the management of rheumatic immune-related adverse events in people with cancer treated with immune checkpoint inhibitors.

29-04-2020 | Rheumatology | News | Article

RA disease activity markers identify patients at risk for worsening ventricular function

The risk for impaired left ventricular systolic function is significantly increased in patients with rheumatoid arthritis if they are positive for anticitrullinated peptide antibody, have high disease activity, and a long duration of disease, study findings suggest.

29-04-2020 | Rheumatology | News | Article

Hydroxychloroquine ‘does not seem to prevent COVID-19’ in people with lupus

The authors of a French case series report the clinical experiences of 17 patients with systemic lupus erythematosus undergoing long-term treatment with hydroxychloroquine who developed COVID-19.

28-04-2020 | Rheumatology | News | Article

Regular glucosamine supplementation may lower mortality risk

Findings from a large prospective cohort study show that regular use of a glucosamine supplement is associated with a reduced risk for all-cause and cause-specific mortality among the general population.

27-04-2020 | Rheumatology | News | Article

COVID-19: FDA warns against chloroquine, hydroxychloroquine use outside specific settings

The US FDA has issued a safety alert warning that chloroquine and hydroxychloroquine for COVID-19 should not be used outside of hospital settings or clinical trials due to an elevated risk for heart rhythm problems with the agents.

27-04-2020 | Rheumatology | News | Article

Phase 2 RA trials ‘systematically overestimate’ treatment efficacy

The reported efficacy of treatments for rheumatoid arthritis is consistently higher in phase 2 than phase 3 randomized controlled trials, mainly due to differences in inclusion criteria, say the authors of a systematic review and meta-analysis.

24-04-2020 | Rheumatology | News | Article

Rheumatologists, patients report healthcare changes during COVID-19 pandemic

Findings from two questionnaire studies suggest that a substantial proportion of rheumatology patients have experienced changes to their disease management since the emergence of COVID-19.

23-04-2020 | Rheumatology | News | Article

Infection-related hospitalizations on the rise among people with gout

The rate of serious infections requiring hospitalization, particularly sepsis, is increasing among people with gout, US longitudinal study data show.

23-04-2020 | Rheumatology | News | Article

COVID-19: Immune effects of rituximab require further investigation

A case report published in the Annals of the Rheumatic Diseases describes the experience of a rituximab-treated patient with ANCA-associated vasculitis who developed severe COVID-19.

Image Credits